Taken together, the above analyses demonstrate an inverse correlation of gain of the SIPL1 gene or high levels of SIPL1 mRNA levels with decreasing survival in patients with PR+ or ER+ breast cancer. The gene discussed is SHARPIN; the disease is breast carcinoma.